Colgate-Palmolive Company

Colgate-Palmolive Company (CL) Market Cap

Colgate-Palmolive Company has a market capitalization of .

No quote data available.

CEO: Noel R. Wallace

Sector: Consumer Defensive

Industry: Household & Personal Products

IPO Date: 1973-05-02

Website: https://www.colgatepalmolive.com

Colgate-Palmolive Company (CL) - Company Information

Market Cap: -|Sector: Consumer Defensive

Company Profile

Operating globally, Colgate-Palmolive Company and its affiliated entities are engaged in the production and distribution of a diverse range of consumer goods. Its operations are structured into two primary divisions: Oral, Personal and Home Care, and Pet Nutrition. The Oral, Personal and Home Care division encompasses a broad array of offerings, spanning oral hygiene (e.g., toothpastes, toothbrushes, mouthwashes), personal care (e.g., bar and liquid soaps, shower gels, shampoos, conditioners, deodorants, antiperspirants, skin health items), and home care solutions (e.g., dishwashing detergents, fabric conditioners, household cleaners). These products are distributed through various channels, including traditional and online retailers, wholesalers, and distributors, under well-known brand names such as Colgate, Darlie, elmex, hello, meridol, Sorriso, Tom's of Maine, Irish Spring, Palmolive, Protex, Sanex, Softsoap, Lady Speed Stick, Speed Stick, EltaMD, Filorga, PCA SKIN, Ajax, Axion, Fabuloso, Murphy, Suavitel, Soupline, and Cuddly. Furthermore, this segment supplies specialized pharmaceutical products to dentists and other professionals in oral healthcare. Conversely, the Pet Nutrition segment focuses on providing specialized pet food. This includes everyday nutritional options marketed under the Hill's Science Diet brand, as well as therapeutic diets designed to assist in managing various health conditions in dogs and cats, sold under the Hill's Prescription Diet brand. Distribution for these pet nutrition items occurs via pet supply stores, veterinary clinics, and online retail platforms. Established in 1806, Colgate-Palmolive Company maintains its corporate headquarters in New York, New York.

Analyst Sentiment

73%
Strong Buy

From 21 Active Polls

1Y Forecast: $96.30

▲ +0.0% Potential Upside

Consensus Target Metrics

Low Bound

$79

Median

$100

High Bound

$102

Average

$96

Price & Moving Averages

Loading chart...

🎯 Wall Street Analyst Intelligence Report

1-Year structural target targets, chart projections, and sentiment maps.

Average 1Y Target
$96.30
▲ +5.48% Upside
Low Target
$79.00
-13% Risk
Median Target
$99.50
9% Mid
High Target
$102.00
12% Max

Consensus Trend Projection

Trailing closures vs. 12-month metrics map.

Analyst Vote Distribution

Aggregate institutional coverage sentiment weights.

Sentiment volume allocation data unavailable.

Historical valuation matrix unavailable.

📘 Full Research Report

ℹ️

AI-Generated Research: This report is for informational purposes only.

📘 COLGATE-PALMOLIVE (CL) — Investment Overview

🧩 Business Model Overview

Colgate-Palmolive produces and sells branded consumer products—primarily oral care (toothpaste, toothbrushes, mouthwash) and also personal care and home care categories in specific geographies. The company monetizes recurring consumer replenishment through a global distribution engine that relies on strong retailer relationships, category leadership, and efficient manufacturing. Demand is driven by habitual use of oral hygiene products, while performance depends on the ability to maintain shelf presence, manage trade promotion intensity, and control input and logistics costs.

💰 Revenue Streams & Monetisation Model

Revenue is overwhelmingly product sales (largely transactional, but with a recurring consumption cadence). The margin structure is shaped by:

  • Gross margin and mix: category leadership and portfolio depth support price/mix resilience when promotions are moderated; premiumization within oral care typically carries better margin than basic SKUs.
  • Operating leverage: scale manufacturing and procurement efficiencies help absorb fixed costs; brand support and trade spend determine the sustainability of operating margins.
  • Channel execution: retailer-funded promotions and consumer-facing pricing actions influence volume and net revenue realization.

Overall monetisation is supported by consistent demand replenishment, while profitability is most sensitive to input costs (commodity-linked inputs), freight/energy, foreign exchange, and the level of promotional intensity required to defend or grow share.

🧠 Competitive Advantages & Market Positioning

Colgate’s moat is primarily rooted in scale/distribution leverage and private-label resistance within oral care and adjacent categories. While toothpaste is not a high switching-cost product in the strict behavioral economics sense, Colgate benefits from durable consumer habits, long-running brand trust, and retailer preference for predictable performance versus store brands.

  • Switching friction via product performance + habit: consumers repurchase based on perceived efficacy (e.g., sensitivity, cavity protection, whitening) and established routines, reducing churn relative to generic alternatives.
  • Distribution leverage: global manufacturing scale and established trade relationships support consistent in-store availability and effective category management.
  • Private-label resistance: private label competes more effectively in price-led segments; replicating branded performance claims, consumer acceptance, and retailer shelf confidence is typically harder and often less margin-friendly.
  • Marketing and innovation flywheel: product line extension and formulation improvements reinforce brand differentiation, supporting shelf space and limiting effective displacement.

COMPETITIVE BENCHMARKING: Key competitors include:

  • Procter & Gamble (P&G): a major oral care rival with strong power in branded toothpaste and toothbrush segments.
  • GlaxoSmithKline (GSK): competes through clinically positioned oral care lines (e.g., sensitivity-oriented propositions).
  • Unilever: competes in personal care and oral care in certain markets, with aggressive promotion strategies.

Colgate’s positioning emphasizes broad category leadership and portfolio depth across geographies, often pairing frequent consumer replenishment categories with disciplined execution in trade channels to protect share against larger multinationals and local/regional brands.

🚀 Multi-Year Growth Drivers

Over a 5–10 year horizon, growth is driven less by a single product cycle and more by structural demand and share/portfolio mix effects:

  • Market expansion from rising oral hygiene awareness: incremental penetration and improved usage frequency in emerging markets supports unit growth.
  • Premiumization within oral care: shift toward differentiated variants (sensitivity, advanced protection, whitening) supports value growth even with mature category volumes.
  • Execution-led share gains: consistent supply, retailer programs, and effective packaging/formulation updates can take share without relying on major price increases.
  • Geographic scaling and channel deepening: broad footprint improves the ability to invest through cycles and defend shelf presence in high-velocity markets.

The business model benefits from durable consumption patterns, enabling management to target growth through mix and distribution strength rather than dependence on one-off demand shocks.

⚠ Risk Factors to Monitor

  • Promotional intensity and share defense economics: prolonged trade spending or consumer price discounting can pressure margins.
  • Input cost volatility and logistics: commodity-linked and energy-linked costs can compress gross margin if not offset by sourcing, mix, or pricing.
  • Foreign exchange translation: international revenue exposure can affect reported results and inventory cost flows.
  • Regulatory and ingredient constraints: labeling, formulation, and claims substantiation requirements can increase compliance costs and limit certain product propositions.
  • Channel and retailer concentration: bargaining power shifts can influence shelf access terms, slotting fees, and promotional funding.

📊 Valuation & Market View

The market generally values consumer staples brands like Colgate using earnings durability and free-cash-flow confidence rather than high growth assumptions. Common valuation frameworks include EV/EBITDA and P/E for steady compounders, with P/S used when investors emphasize revenue stability and margin trajectory. Key variables that tend to move the valuation multiple include:

  • Sustainable gross margin: ability to manage input costs and protect product mix.
  • Operating margin durability: discipline in trade spend and brand investment efficiency.
  • Volume vs. price mix: share gains and premiumization can support revenue quality.
  • Capital return capacity: consistent cash generation supports dividends and buybacks, which can anchor investor expectations.

🔍 Investment Takeaway

Colgate-Palmolive is a durable consumer staples franchise with an investment case anchored in distribution scale, private-label resistance, and portfolio-driven differentiation within oral care—categories supported by habitual, recurring consumption. The long-term opportunity is primarily derived from premiumization and geographic penetration, while the main downside risks stem from promotional pressure, cost volatility, and retailer/channel bargaining dynamics.


⚠ AI-generated — informational only. Validate using filings before investing.

📊 AI Financial Analysis

Powered by StockMarketInfo
Earnings Data: Q Ending 2026-06-30

"Headline (2026-06-30, Q2): Revenue $5.361B, EPS $0.87, Net Income $693M (net margin 12.9%). YoY (vs 2025-06-30): Revenue +4.8% and Net Income -10.5% (EPS +~ -5.4% implied by 0.92 to 0.87). QoQ (vs 2026-03-31): Revenue +0.7% and Net Income +7.3% (EPS 0.81 to 0.87). Profitability was mixed over the quarter: gross margin improved (61.5% vs 60.6% QoQ) while operating/net margins modestly contracted (net margin 12.1% to 12.9% actually expanded QoQ, but YoY net margin is lower vs ~14.5% in Q2’25). Cash flow quality remained strong: operating cash flow $995M and free cash flow (FCF) $867M, both up QoQ (OCF +33% and FCF +42%). The company returned substantial capital—dividends paid $462M and buybacks $306M in Q2—while maintaining strong interest coverage (~16x). Balance sheet resilience appears pressured by leverage optics: total assets were $16.79B and equity was very low ($0.566B), with net debt $6.49B slightly down QoQ. Total shareholder return is supported by ongoing buybacks/dividends, but market momentum is negative: price is down 8.21% over 1 year, so there is no >20% momentum boost. Analyst valuation appears roughly in line to modestly below consensus target (~$96.3) versus current ~$85.81."

Revenue Growth

Positive

Revenue grew QoQ +0.7% ($5.324B to $5.361B) and YoY +4.8% ($5.110B to $5.361B), indicating steady top-line momentum despite a softer earnings YoY.

Profitability

Neutral

Net income rose QoQ +7.3% ($646M to $693M) and net margin improved to 12.9% (vs 12.1% QoQ). However, YoY net income declined -10.5% (and net margin is lower than ~14.5% in Q2’25), suggesting margin/expense pressures year-over-year.

Cash Flow Quality

Good

Operating cash flow of $995M and FCF of $867M were strong and improved QoQ (OCF +33%, FCF +42%). Capital returns (dividends $462M, buybacks $306M) were well supported by cash generation; no cash-flow stress evident.

Leverage & Balance Sheet

Caution

Leverage remains elevated with net debt $6.49B. Equity is thin ($0.566B) though it improved QoQ; total assets rose slightly to $16.79B. Interest coverage is healthy (~16x), but the equity structure keeps balance-sheet optics weaker.

Shareholder Returns

Positive

Dividend payments ($462M) plus buybacks ($306M) support shareholder returns. Market price performance is negative over 1Y (-8.21%), so total return is moderated versus a momentum-backed scenario.

Analyst Sentiment & Valuation

Neutral

Consensus target ($96.3) is above the current price (~$85.81), implying potential upside. However, high multiples (e.g., P/E ~26x from ratios) suggest expectations are already embedded.

Disclaimer:This analysis is AI-generated for informational purposes only. Accuracy is not guaranteed and this does not constitute financial advice.

Fundamentals Overview

Loading fundamentals overview...

Colgate-Palmolive started 2026 with accelerating organic volume growth, led by emerging markets and Asia Pacific, including improving execution at Hawley & Hazel. Management emphasized advertising ROI and RGM discipline, sustaining brand investment despite sluggish category demand globally. The primary financial pressure is gross margin: guidance reflects embedded cost inflation with oil assumed around $110 and ~$300M additional raw materials/logistics impact (including logistics up nearly 10%). Tariffs are a key North America driver, with Q1 comparisons against minimal prior-year tariffs and normalization expected as the year progresses. Despite margin headwinds, EPS guidance confidence remains supported by RGM productivity and other cost flexibility (including SGPP productivity and structural simplification tied to the $200M–$300M savings target ending 2028). North America is the clearest execution risk, but management expects sequential improvement as shelf/reset timing issues clear and innovation ramps. Hill’s momentum remains a bright spot even as dry dog lags. Sentiment is mixed due to margin/tariff risk versus strong volume and emerging-market resilience.

AI IconGrowth Catalysts

  • Emerging markets acceleration with Asia Pacific as key driver; broad-based volume growth across almost all divisions and categories (except sluggish categories overall).
  • Hawley & Hazel execution improvements in Asia (dual tube technology/innovation, improved omnichannel execution including Douyin).
  • RGM (pricing/value actions) plus advertising-funded volume share gains in emerging markets and Latin America.
  • Innovation-led growth expansion across price points in emerging markets; premium opportunity alongside lower/mid-pricepoint initiatives.
  • Hill’s strong momentum: 4.8% organic volume+price ex private label ex private label at total, with Science Diet and Prescription Diet delivering double-digit growth in targeted areas.

Business Development

  • Hawley & Hazel (Asia Pacific business) intervention strategy referenced as driving improving execution; no named external partner provided.
  • Hill’s distribution gains tied to retailers: shelf space gaining attributed to innovation growth (retailer relationship improvement referenced; no named retailer).
  • Mentioned omnichannel execution on Douyin (platform partnership referenced implicitly via channel execution).

AI IconFinancial Highlights

  • Organic sales growth guidance maintained at 1% to 4% for full year despite pressured gross margins.
  • Gross margin pressure guidance change attributed to embedded cost inflation and tariff impacts; management explicitly states margins likely down for the year.
  • Embedded macro assumptions: oil roughly $110 for the balance of the year; incremental $300 million impact across raw materials and logistics (including logistics in the number).
  • Incremental cost detail: $300 million additional raw materials/logistics impact (roughly 2/3 raw materials, 1/3 logistics). Logistics costs up nearly 10% (ocean and land freight).
  • Oil-byproduct spend assumptions: resins, petrochemicals, fats and oils expected up more than 20% YoY for the full year.
  • North America gross margin pressure attributed to tariffs: year-over-year comparison versus prior year with minimal tariffs; tariff impact expected to lessen as year progresses.
  • Private label pet food exit impacts: private label 260 bps negative, tapering to 20-30 bps negative impact in Q2; expected to be out by back half of year.

AI IconCapital Funding

    AI IconStrategy & Ops

    • Strategic growth and productivity program update: $200 million to $300 million annualized savings target; majority expected in 2027 and 2028; not an extension (still expected to complete end of 2028).
    • Savings to fund 2030 strategy investments (capabilities/innovation) and bottom-line contribution; intent to drive consistent compounded dollar-based EPS growth.
    • Operational structure changes to reduce complexity for an “agile company” designed for omnichannel environment.
    • RGM productivity across the P&L and other productivity initiatives outside SGPP; productivity expected to impact both cost line and SG&A flexibility.

    AI IconMarket Outlook

    • Full-year organic sales growth guidance maintained at 1% to 4%.
    • Management expects North America sequential improvement and margin pressure normalization as tariffs normalize through the year.
    • Private label negative impact taper: 260 bps (Q1) → 20-30 bps (Q2) → out by back half of 2026.

    AI IconRisks & Headwinds

    • Significant increases in raw material and packaging costs built into guidance, pressuring gross margin.
    • Tariff headwind concentrated in North America; Q1 lapping benefited prior year minimal tariffs, while year-over-year impact expected to be less going forward.
    • Consumer/environment uncertainty: oil location and interest rates; category volumes still “sluggish” globally.
    • North America competition: competitor spending more on couponing to drive volume; Hill’s category dry dog segment slipping.

    Q&A: Analyst Interest

    • Cost inflation embedded in guidance: Management quantified oil at ~$110 average for remainder of year, with ~$300M incremental raw materials/logistics impact (2/3 raw, 1/3 logistics), logistics up nearly 10%, and oil-byproducts spend up >20% YoY; RGM productivity offsets maintained.
    • North America recovery plan: Management expects sequential volume and market-share improvement; interventions include brand interventions, accelerated innovation, RGM, improved execution, and better promotion strategy with key retailers; shelf resets and new product shipments arriving late dampened early-quarter volume, with acceleration in exiting quarter and second half.
    • Private label pet food exit + Hill’s traction: Management stated private label created a 260 bps negative headwind in Q1, tapering to 20–30 bps in Q2 and exiting by back half of year; Hill’s grew 4.8% organic ex private label, with Prescription Diet double-digit in targeted indications and broad channel/segment share gains.

    Sentiment: MIXED

    Note: This summary was synthesized by AI from the CL Q1 2026 earnings transcript. Financial data is complex; please verify all metrics against official SEC filings before making investment decisions.

    Loading financial data and tables...
    © 2026 Stock Market Info — Colgate-Palmolive Company (CL) Financial Profile